These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17435644)

  • 1. Are various Babesia species a missed cause for hypereosinophilia? A follow-up on the first reported case of imatinib mesylate for idiopathic hypereosinophilia.
    Schaller JL; Burkland GA; Langhoff PJ
    MedGenMed; 2007 Feb; 9(1):38. PubMed ID: 17435644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
    Payne SM; Kovacs MJ
    Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
    Schaller JL; Burkland GA
    MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses.
    Smith KJ; Jacobson E; Hamza S; Skelton H
    Arch Dermatol; 2004 May; 140(5):584-8. PubMed ID: 15148104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fever of unknown origin (FUO) due to babesiosis in a immunocompetent host.
    Cunha BA; Cohen YZ; McDermott B
    Heart Lung; 2008; 37(6):481-4. PubMed ID: 18992633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib-responsive hypereosinophilia in a patient with B cell ALL.
    Robyn J; Noel P; Wlodarska I; Choksi M; O'neal P; Arthur D; Dunbar C; Nutman T; Klion A
    Leuk Lymphoma; 2004 Dec; 45(12):2497-501. PubMed ID: 15621767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D; Hwang W; Ng HJ; Goh YT; Tan P
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report.
    Vyas JM; Telford SR; Robbins GK
    Clin Infect Dis; 2007 Dec; 45(12):1588-90. PubMed ID: 18190320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
    Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hypereosinophilic syndromes: still more heterogeneity.
    Gleich GJ; Leiferman KM
    Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen.
    Häselbarth K; Tenter AM; Brade V; Krieger G; Hunfeld KP
    Int J Med Microbiol; 2007 Jun; 297(3):197-204. PubMed ID: 17350888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reader's response to "Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate".
    Shinkarow JW
    MedGenMed; 2007; 9(1):39. PubMed ID: 17441290
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
    Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
    Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atovaquone and azithromycin treatment for babesiosis in an infant.
    Raju M; Salazar JC; Leopold H; Krause PJ
    Pediatr Infect Dis J; 2007 Feb; 26(2):181-3. PubMed ID: 17259886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The hypereosinophilic syndrome: case report].
    Mikołajczyk K; Zaba R; Walkowiak B; Grzybowski G; Samborski W
    Ann Acad Med Stetin; 2006; 52 Suppl 2():65-9. PubMed ID: 17471838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.
    Wormser GP; Prasad A; Neuhaus E; Joshi S; Nowakowski J; Nelson J; Mittleman A; Aguero-Rosenfeld M; Topal J; Krause PJ
    Clin Infect Dis; 2010 Feb; 50(3):381-6. PubMed ID: 20047477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib.
    Garcia-Alvarez A; Sitges M; Garcia-Albeniz X; Sionis A; Loma-Osorio P; Bosch X
    Int J Cardiol; 2010 Mar; 139(2):e29-31. PubMed ID: 19056137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.